Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT06406114
Anaphylaxis, Antibiotic Allergy
Scottsdale, Arizona, United States
View Trial DetailsNCT Number: NCT04330118
Drug Hypersensitivity Syndrome or DRESS for "Drug Reaction with Eosinophilia and Systemic Symptoms" is a serious drug allergy which can be life-threatening for patients with serious organ damage. The pathophysiology of DRESS is still not fully understood. In particular, no study has focused on the characterization of eosinophils, while paradoxically eosinophilia is one of the diagnostic criteria. Likewise, there is no data about the origin of eosinophils and few data are available concerning immune polarization of T-cells or the involvement of innate lymphoid cells type 2 in the recruitment of eosinophils. Our preliminary data on increase activation markers membrane expression of cutaneous eosinophils suggest that this approach could allow the identification of endotypes in which eosinophils are involved and contribute to organ damages. The correlation between tissue infiltration of eosinophils and their degree of activation would then justify the development of targeted therapeutic strategies in DRESS syndrome (anti-IL-5 therapy?). The aim of the project is: 1) Evaluate the activation status of circulating and cutaneous eosinophils in patients with DRESS compared with drug induced maculopapular exanthema without or with eosinophilia (but do not fulfill DRESS criteria) and healthy subjects; 2) Understand the pathophysiological mechanisms at the origin of this eosinophilia.
Interested in participating?
Request Info18 year and older
All sexes
Observational
CH d'Arras, Arras, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Group 1 (DRESS): adult with a diagnosis of DRESS based on the following four criteria:
Groups 2 and 3 (Drug induced maculopapular exanthema without or with eosinophilia).
Group 2 (MPE without eosinophilia): blood eosinophils < 500 / mm3
Group 3 (MPE with eosinophilia): blood eosinophils ≥ 500 / mm3
Exclusion criteria
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline and 3 months
Contact information is provided by the study sponsor or research team.
University Hospital, Lille
Other
Origin and Function of Eosinophilic Polynuclear During Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome
Acronym: DRESSEO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06406114
Anaphylaxis, Antibiotic Allergy
Scottsdale, Arizona, United States
View Trial DetailsNCT07069439
Allergy and Immunology, Caregivers
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03771118
Chemically-Induced Disorders, Drug Hypersensitivity
Montpellier, France
View Trial DetailsNCT07390370
Chemically-Induced Disorders, Drug Hypersensitivity
View Trial Details